CL2023001223A1 - Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo - Google Patents

Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo

Info

Publication number
CL2023001223A1
CL2023001223A1 CL2023001223A CL2023001223A CL2023001223A1 CL 2023001223 A1 CL2023001223 A1 CL 2023001223A1 CL 2023001223 A CL2023001223 A CL 2023001223A CL 2023001223 A CL2023001223 A CL 2023001223A CL 2023001223 A1 CL2023001223 A1 CL 2023001223A1
Authority
CL
Chile
Prior art keywords
preparing
crystal form
receptor agonist
melanocortin receptor
agonist compound
Prior art date
Application number
CL2023001223A
Other languages
English (en)
Inventor
Ok HAM Jin
Yeon Lee Ho
Yoon Kim Ji
Won Kim Sung
Ah CHUN Seul
Dae Lee Sang
Won Park Jong
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2023001223A1 publication Critical patent/CL2023001223A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a la forma cristalina I de un compuesto representado por la fórmula química 1, a un procedimiento para su preparación y a una composición farmacéutica que lo comprende. La forma cristalina I del compuesto representado por la fórmula química 1 de la presente invención puede caracterizarse por un patrón XRD, un perfil DSC y/o un perfil TGA.
CL2023001223A 2020-10-29 2023-04-27 Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo CL2023001223A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200142396 2020-10-29

Publications (1)

Publication Number Publication Date
CL2023001223A1 true CL2023001223A1 (es) 2023-11-03

Family

ID=81384109

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001223A CL2023001223A1 (es) 2020-10-29 2023-04-27 Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo

Country Status (14)

Country Link
US (1) US20230373984A1 (es)
EP (1) EP4219472A4 (es)
JP (1) JP2023548327A (es)
KR (2) KR102672624B1 (es)
CN (1) CN116507615A (es)
AU (1) AU2021367713B2 (es)
CA (1) CA3195298A1 (es)
CL (1) CL2023001223A1 (es)
CO (1) CO2023006515A2 (es)
IL (1) IL302427A (es)
MX (1) MX2023004655A (es)
PE (1) PE20240048A1 (es)
WO (1) WO2022092909A1 (es)
ZA (1) ZA202305594B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI814185B (zh) * 2020-12-22 2023-09-01 南韓商Ｌｇ化學股份有限公司 黑皮質素受體促效劑化合物之晶型ii及其製備方法
US20240043407A1 (en) * 2020-12-22 2024-02-08 Lg Chem, Ltd. Crystalline form i of melanocortin receptor agonist compound and method for preparing same
KR20220090458A (ko) * 2020-12-22 2022-06-29 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법
WO2022235104A1 (ko) * 2021-05-06 2022-11-10 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법
CA3217198A1 (en) * 2021-05-07 2022-11-10 Lg Chem, Ltd. Sulfate crystals of melanocortin receptor agonist compound and method of producing same
US20240239769A1 (en) * 2021-05-07 2024-07-18 Lg Chem, Ltd. Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074679A1 (en) * 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7157463B2 (en) * 2001-01-23 2007-01-02 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
KR100661118B1 (ko) * 2003-11-12 2006-12-26 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
KR20080007046A (ko) * 2006-07-14 2008-01-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
BR112019016488B1 (pt) 2017-02-08 2022-11-16 Tilray, Inc Método e aparato para processamento de cannabis com energia radiante de baixa pressão
UA127255C2 (uk) * 2019-11-07 2023-06-21 Елджі Кем, Лтд. Агоністи рецептора меланокортину-4

Also Published As

Publication number Publication date
WO2022092909A1 (ko) 2022-05-05
EP4219472A1 (en) 2023-08-02
PE20240048A1 (es) 2024-01-09
AU2021367713A9 (en) 2024-04-18
KR20240085230A (ko) 2024-06-14
AU2021367713A1 (en) 2023-06-01
KR20220057470A (ko) 2022-05-09
JP2023548327A (ja) 2023-11-16
MX2023004655A (es) 2023-05-18
CO2023006515A2 (es) 2023-07-31
CN116507615A (zh) 2023-07-28
KR102672624B1 (ko) 2024-06-07
AU2021367713B2 (en) 2024-01-25
CA3195298A1 (en) 2022-05-05
US20230373984A1 (en) 2023-11-23
EP4219472A4 (en) 2024-03-13
ZA202305594B (en) 2024-09-25
IL302427A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
CL2023001223A1 (es) Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006513A2 (es) Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CO2023006517A2 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación para la misma
BRPI0804994A2 (pt) forma cristalina vi de agomelatina, um processo para a sua preparação e composições farmacêuticas contendo-a
UY33317A (es) Nuevos derivados de pirazol
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
ZA202000411B (en) Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
AR066158A1 (es) COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE.
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
UY36746A (es) Método para la síntesis de derivados de rapamicina
CO2023006514A2 (es) Agonista de receptor de melanocortina-4 amorfo
DOP2021000074A (es) Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contiene la misma
CL2021002205A1 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
CL2020001346A1 (es) Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción.
PE20211756A1 (es) FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
BR112023022863A2 (pt) Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
BR112015031945A2 (pt) processos para a preparação de compostos
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
MX2023013044A (es) Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
BR112018009029A8 (pt) corante, método para a produção de um corante, composição, artigo manufaturado e uso de um corante
MX2023013129A (es) Forma cristalina iv de sales de acidos organicos del compuesto agonista del receptor de melanocortina y metodo de preparacion de este.
BR112023022334A2 (pt) Formas cristalinas de sulfato do composto agonista do receptor de melanocortina, seus métodos de preparação, seus usos, e composições farmacêuticas compreendendo as mesmas